1. Introduction {#sec1}
===============

*SRD5A2*, the gene encoding steroid 5*α*-reductase type 2 (5*α*-RD2), is located on chromosome 2p23 and contains 5 exons \[[@B1]\]. 5*α*-RD2 contains 254 amino acids and is predominantly expressed in fetal genital skin, male productive tissues, and the prostate \[[@B2]\]. It converts testosterone (T) to dihydrotestosterone (DHT), which plays a vital role in the development of male external genitalia \[[@B3]\].

5*α*-RD2 deficiency is an autosomal recessive disorder caused by mutations in the *SRD5A2* gene that impair the conversion of T to DHT. Since first described in 1974 \[[@B4], [@B5]\], more than 100 mutations of *SRD5A2* have been identified worldwide \[[@B6]--[@B8]\]. Phenotypes of 5*α*-RD2 deficiency range from female external genitalia to hypospadias with microphallus to apparently normal male external genitalia. After puberty, these patients showed different degrees of virilization and often change their social gender from female to male \[[@B9]\].

In some cases, 5*α*-RD2 deficiency shared the same clinical phenotype with androgen insensitivity syndrome, which may have caused misdiagnosis of this disease. Elevated baseline and hCG-stimulated T/DHT ratio is useful to diagnose this disease \[[@B10]--[@B12]\]. However, more accurate diagnoses rely on genetic testing, especially in prepubertal patients \[[@B13]\].

In this study, we analyzed 25 Chinese patients with 5*α*-RD2 deficiency. Eighteen mutations in the *SRD5A2* gene were identified from these patients. In these mutations, p.Gln6∗ was widely reported. Therefore, we chose 12 SNPs near p.Gln6∗ and performed haplotype analysis to determine whether this mutation has a founder effect in the Chinese population.

2. Patients and Methods {#sec2}
=======================

2.1. Patients {#sec2.1}
-------------

Twenty-five patients, aged from 4 days to 34 years (diagnosis age), with 46,XY DSD were included in this study. Patients 1-14 were reported by Cheng et al. \[[@B14]\]. Patients 15-25 were reported by Zhu et al. \[[@B9]\]. Patients 4 and 17 came from consanguineous families. Patients 8 and 9 were twin brothers with similar phenotypes, whereas patients 21 and 22 were siblings with different phenotypes. The clinical and definitive diagnosis of steroid 5*α*-reductase-2 deficiency was described previously \[[@B9]\]. External masculinization score (EMS) was also accessed as previously described \[[@B15]\]. This study was approved by the Ethics Committee of our institute. Written informed consent was obtained from all the adult patients themselves or from the parents of patients who were children.

2.2. Mutation Analysis {#sec2.2}
----------------------

Genomic DNA of the patients was extracted from peripheral blood leukocytes using a kit (TIANGEN Biotech, Beijing, China). All five exons of the *SRD5A2* gene were amplified as previously described \[[@B9]\]. Then, the PCR products were purified by shrimp alkaline phosphatase (SAP, USB, Cleveland, USA) and directly sequenced in both directions. When a novel mutation was found, PCR fragments amplified from the genomic DNA of 100 healthy subjects were also analyzed to exclude polymorphism.

2.3. Haplotype Analysis {#sec2.3}
-----------------------

For haplotyping analysis, 12 common single-nucleotide polymorphisms (SNPs) near the location of p.Gln6∗ were selected from the *SRD5A2* gene based on the genotyping data from 1468 Chinese Han individuals in a genome-wide association study (GWAS) \[[@B16]\] (rs12470143: SRD5A2 RefSeq Gene NG_008365.1:g.47484G\>A; rs12470196: SRD5A2 RefSeq Gene NG_008365.1:g.47290G\>A; rs57971483: SRD5A2 RefSeq Gene NG_008365.1:g.45532A\>G; rs4952220: SRD5A2 RefSeq Gene NG_008365.1:g.45486G\>A; rs2300697: SRD5A2 RefSeq Gene NG_008365.1:g.24405G\>A; rs2300698: SRD5A2 RefSeq Gene NG_008365.1:g.24249T\>C; rs2300699: SRD5A2 RefSeq Gene NG_008365.1:g.24075C\>A; rs2300700: SRD5A2 RefSeq Gene NG_008365.1:g.24050C\>T; rs2300701: SRD5A2 RefSeq Gene NG_008365.1:g.24034T\>C; rs522638: SRD5A2 RefSeq Gene NG_008365.1:g.5367T\>C; rs523349: SRD5A2 RefSeq Gene NG_008365.1:g.5336C\>G; rs632148: SRD5A2 RefSeq Gene NG_008365.1:g.5010G\>C) (<http://www.ncbi.nlm.nih.gov/SNP/>). Two twin brothers (patients 8 and 9) had the same genotype. Therefore, six patients carrying the p.Gln6∗ heterozygous mutation were genotyped for these 12 SNPs by PCR and Sanger sequencing. PHASE 2.1 software was used to perform the haplotyping analysis. We also compared the difference in haplotypes between healthy controls and our patients.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Data were expressed as the means ± SD. Statistical analysis was determined using the unpaired Student\'s *t*-test. The analyses were performed using SPSS version 11.0. *P* \< 0.05 was considered significant.

3. Results {#sec3}
==========

3.1. Clinical Characteristics {#sec3.1}
-----------------------------

The molecular analysis results of 25 patients with 5*α*-RD2 deficiency are summarized in [Table 1](#tab1){ref-type="table"}. The detailed clinical characteristics were described previously \[[@B9], [@B14]\]. Seventeen of the 25 patients (68%) were initially raised as females. Among them, 16 patients (94.1%) had changed their social gender from female to male. Six patients were prepubertal (patients 10, 11, 15, 16, 17, and 18), and only one (patient 15) was raised as a male before the first examination. Nineteen patients were diagnosed at the age of more than 16 years old. Patients 21 and 22 were siblings but presented with different phenotypes. Isolated micropenis or normal female genitalia were found in patients 16 and 22. The topical application of DHT gel was used by patients 3, 4, 5, 10, 16, and 20 with different diagnostic ages. Six patients were from Guizhou province and four patients were from Jiangxi province. Of the seven patients with p.Gln6∗ mutation, three were from Guizhou province and the other four patients were from Sichuan, Anhui, Hubei, and Shandong provinces.

3.2. DNA Sequencing {#sec3.2}
-------------------

Eighteen different mutations were identified in 25 patients from 23 unrelated families ([Table 1](#tab1){ref-type="table"}). Compound heterozygous mutations were found in 15 patients, and homozygous mutations were found in 7 patients. The most frequent mutations in our study was p.Gly203Ser and p.Gln6∗, found on one allele of 8 (patients 2, 4, 10, 16, 20, 21, 22, and 25) and 7 patients (patients 1, 6, 8, 9, 11, 12, and 25). The reported polymorphism, p.Val89Leu, was identified in 14 patients.

3.3. Comparison of Hormone Levels and EMS between Different Mutation Types {#sec3.3}
--------------------------------------------------------------------------

To investigate the influence of "hotspot" mutations p.Gly203Ser and p.Gln6∗ on hormone levels, we compared patients with these two mutations and those without the two mutations. In a comparison of 8 patients carrying the p.Gly203Ser mutation and 17 patients carrying other mutations, LH, FSH, T, DHT, T/DHT, and EMS showed no significant difference (*P* ≥ 0.05) in [Table 2](#tab2){ref-type="table"}. We also compared 7 patients carrying the p.Gln6∗ mutation and 18 patients without the p.Gln6∗ mutation. The results indicated that LH, FSH, T, DHT, and T/DHT were not significantly different (*P* ≥ 0.05). However, EMS showed marginal difference between two groups (*P* = 0.05) ([Table 3](#tab3){ref-type="table"}).

3.4. Haplotype Analysis {#sec3.4}
-----------------------

The heterozygous nonsense mutation p.Gln6∗, which was the most frequent mutation in this study, was identified in 7 cases from 6 pedigrees (7/25, 28%). To identify potential common ancestors for those subjects who carried this mutation, twelve SNPs in and around exon 1 of *SRD5A2* spanning 26 kb were chosen for analysis. Three haplotypes were observed in 6 patients (12 alleles), with CCTCCAGGAAGC and TTCATGTAGGCG in 5 alleles, respectively, whereas CCTCTGTGGGCG were found in 2 alleles. It cannot be concluded that the p.Gln6∗ mutation has a founder effect in the Chinese population since in 6 alleles carrying the p.Gln6∗ mutation, two different haplotypes were found (haplotype 1 and haplotype 3), and haplotype 1 was also found to be common in 1494 normal alleles ([Table 4](#tab4){ref-type="table"}).

4. Discussion {#sec4}
=============

DHT, converted from testosterone in the skin of the fetal labioscrotal folds as a paracrine factor, induces labioscrotal fusion, the development of the phallic urethra, and phallic enlargement \[[@B17]\]. Two 5*α*-reductases in humans, encoded by different genes on chromosome 5 and chromosome 2 (*SRD5A1* and *SRD5A2*), were identified to catalyze the conversion of testosterone to DHT. Both enzymes are hydrophobic and membrane bound \[[@B1]\] and have proven difficult to solubilize in active form. With a similar gene structure of 5 exons separated by 4 introns, *SRD5A2* was found to be predominantly expressed in the male urogenital tract and prostate and in female genital skin, whereas *SRD5A1* is predominantly expressed in the ovary, testis, liver, and nongenital skin. It is well known that dehydroepiandrosterone (DHEA) and androstenedione or androstenediol are key intermediates in the synthesis of testosterone, and fetal DHT is produced in situ in its target organ in the "classic" pathway of androgen synthesis. Recently, an alternative, or "backdoor," biosynthetic pathway was reported to exist, leading to the production of DHT in the fetal testis, in which progesterone was converted to 5*α*-dihydroprogesterone by SRD5A1 and 3*α*-hydroxysteroid dehydrogenase (aldo-keto reductase (AKR)) \[[@B18], [@B19]\]. The finding that human *AKR1C2* mutations can result in 46,XY DSD shows that DHT produced in the fetal testis via the backdoor pathway acts as a hormone that collaborates with DHT produced in the genital skin by *SRD5A2* to induce labioscrotal fusion \[[@B19]\].

In patients 1 and 2, they all have three mutations. In the first patient, a cloning experiment indicated that p.Gln6∗and p.Lys35Asn were located in the same chromosome. Due to the severe truncating mutation at codon 6 (p.Gln6∗), the latter mutation (p.Lys35Asn) could not be expressed in the mature protein. So, p.Gln6∗ and p.Phe234Leu were pathogenic mutations in this patient. In the second patient, p.Gly203Ser and p.Arg227Gln were located in different chromosomes. We cannot perform a cloning test because of the long distance between p.Gly34Arg and p.Gly203Ser/p.Arg227Gln on the chromosome. In a previous study, functional analysis showed that p.Gly34Arg only retained about 1.2% of the enzyme activity \[[@B20]\]. So, all three mutations caused inactivity of the enzyme in the second patient.

To be noted, 17 (68%) out of 25 patients were raised initially as females in our study. Of these 17 patients, 16 (94.1%) changed their social gender to male. However, the ratios of female social sex and female-to-male sex change range from 77 to 93% and 12 to 50%, respectively, in Brazilian and French studies \[[@B21]\]. In a Chinese study, Song et al. analyzed 86 children (age 2 months to 17 years) with 5*α*-reductase deficiency and found that 27 (31.4%) out of the 86 patients were raised as females \[[@B22]\]. Cheng et al. found 4 (8.9%) out of 45 Chinese patients (age 3 months to 12 years) were raised as females \[[@B23]\]. These two Chinese studies did not refer to the female-to-male social sex change. The female social sex ratio of our patients was similar to that in a French study \[[@B24]\] but was higher than those in two Chinese studies. However, the ratio of female-to-male sex change in our study was obviously higher than those in Brazilian and French studies. This might be attributed to the age of diagnosis \[[@B21]\]. In the Brazilian and French studies, the patients were diagnosed at an average age of 16 and 7.6 years old, respectively. Thus, the prevalence of social sex alteration in the Brazilian study was higher than that in the French study (50% vs. 12%). In our study, 19 patients (76%) were older than 16 years and the average age at diagnosis was 18 years. So the ratio of social sex change was higher than the Brazilian study. Besides that, most of our patients were from remote areas (such as Guizhou and Jiangxi) and presented with female external genitalia. Poor medical conditions and insufficient attention of parents might also be considered.

In our study, p.Gly203Ser and p.Gln6∗ were the most common mutations. p.Gly203Ser was identified in 8 patients with an allele frequency 20.8% and was homozygous in nonconsanguineous patients 4 and 10. Zhang et al. \[[@B25]\] identified the heterozygous mutation p.Gly203Ser in 3 patients and presumably suggested a founder effect in the Chinese population. However, in our previous study \[[@B9]\], we found that p.Gly203Ser in *SRD5A2* was the most prevalent mutation and that there was no founder effect of this mutation in the Chinese population. In this study, seven patients from 6 unrelated families were heterozygous for the nonsense mutation p.Gln6∗, which was reported mainly in East Asia.

For haplotype analysis, we selected 12 SNPs near p.Gln6∗ based on the genotyping data from 1468 Chinese Han individuals in GWAS data \[[@B16]\]. Actually, these 12 SNPs could form more than 3 haplotypes, but we only listed 3 haplotypes which were found in 6 patients with p.Gln6∗ mutation in [Table 4](#tab4){ref-type="table"}. Mutant allele T (p.Gln6∗) could be found both in haplotypes 1 (5 alleles) and 3 (1 alleles). Moreover, wild genotype C and mutant genotype T simultaneously presented in haplotype 3. So, there was no linkage disequilibrium between p.Gln6∗ and the other 12 SNPs. Besides, no geographic relationship was found in 5 patients who shared haplotype 1. Therefore, p.Gln6∗ does not appear to derive from a common ancestor in the Chinese population, which is consistent with the fact that it has been reported in Mexico, China, Korea, and Thailand \[[@B8], [@B9], [@B13], [@B26]\]. The recurrence of a particular mutation in a geographically isolated region suggests a founder effect; for example, two specific *CYP17A1* mutations in China or East Asia have been rarely reported in other ethnic groups \[[@B27], [@B28]\]. Similarly, two population-specific mutations in *CYP17A1* (p.Trp406Arg and p.Arg362Cys) also showed a founder effect in Brazil \[[@B29]\].

The p.Arg246Gln substitution that we found in patients 3, 17, 18, and 19 seems to be a hot spot of *SRD5A2* mutations since it has been reported in patients with diverse geographic and ethnic backgrounds, including those with Korean, Indian, Mexican, and Italian ethnic backgrounds \[[@B13], [@B30]--[@B32]\]. Eunice et al. \[[@B33]\] even proposed a founder gene effect of this mutation in India. Functional studies of this mutation suggested that it decreases the affinity for the cofactor NADPH \[[@B1], [@B34]\]. The optimal pH of the mutant enzyme is also changed, resulting in a disruption of the activity of the enzyme. Missense mutations that result in less than 0.4% activity of the 5*α*-reductases usually result in ambiguous or female external genitalia \[[@B26]\]. p.Arg227Gln was also detected in four patients (patients 2, 10, 13, and 15). Cheng et al. \[[@B23]\] reported that the p.Arg227Gln mutation was most frequently reported (91.1%) in South China, which suggested a founder effect. However, the incidence of p.Arg227Gln was relatively lower in our cohort (4/25).

There were some less frequent mutations detected in our study, such as p.Gly34Arg and c.182-2A\>G. p.Gly34Arg was identified only in one patient (patient 2). However, this mutation was prevalent in Egypt and had linkage disequilibrium with the V89L polymorphism, which indicated a founder effect of the p.Gly34Arg mutation among Egyptians \[[@B35]\]. A c.182-2 A\>G mutation was detected in a set of siblings (patients 21 and 22); this mutation is common in Greek-Cypriot patients with 5*α*-reductase deficiency and is very likely to be the result of a founder effect \[[@B36], [@B37]\]. Vilchis et al. \[[@B38]\] analyzed 11 Mexican patients with steroid 5*α*-reductase 2 deficiency. They found that 40% of the mutant alleles (9/22) contained the gene variant p.Pro212Arg and hypothesized that the presence of this mutation may constitute a founder gene effect. However, we did not discover this mutation in our cohort.

5. Conclusion {#sec5}
=============

Eighteen mutations were identified in 25 Chinese patients with 5*α*-RD2 deficiency. p.Gln6∗ and p.Gly203Ser were the most prevalent mutations. Although no homozygous p.Gln6∗ mutation and only two homozygous p.Gly203Ser mutations were included, the patients with or without p.Gln6∗ and p.Gly203Ser did not demonstrate a significant difference in hormone levels. Finally, no founder effect of the p.Gln6∗ mutation in the *SRD5A2* gene was detected in the Chinese population.
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###### 

Clinical and genetic characteristics of the patients.

  Patient no.   Location   Age of diagnose   Sex of rearing at birth   EMS   *SRD5A2* mutation
  ------------- ---------- ----------------- ------------------------- ----- ------------------------------------
  1             Sichuan    22 yr             F to M                    3     p.Gln6∗/p.Lys35Asn/p.Phe234Leu
  2             Guizhou    23 yr             M                         6     p.Gly203Ser/p.Arg227Gln/p.Gly34Arg
  3             Sichuan    20 yr             M                         5     p.Leu20Pro/p.Arg246Gln
  4             Jiangxi    19 yr             M                         6     p.Gly203Ser/p.Gly203Ser
  5             Liaoning   23 yr             F to M                    2     p.Ala228Val/\-\--
  6             Guizhou    24 yr             F                         2     p.Gln6∗/\-\--
  7             ---        30 yr             M                         2     p.Tyr136∗/p.Tyr136∗
  8             Guizhou    18 yr             F to M                    2     p.Gln6∗/p.His162Pro
  9             Guizhou    18 yr             F to M                    2     p.Gln6∗/p.His162Pro
  10            Guizhou    5 yr              F to M                    2     p.Gly203Ser/p.Gly203Ser
  11            Anhui      11 yr             F to M                    2     p.Gln6∗/p.Arg227Gln
  12            Hubei      23 yr             F to M                    2     p.Gln6∗/p.Asn193Ser
  13            Yunnan     18 yr             M                         5     p.Arg171Ser/p.Gly196Val
  14            Guizhou    34 yr             F to M                    3     p.Leu20Pro/p.Arg227∗
  15            Jiangxi    4 yr              M                         9     p.Val89Leu/c.655del
  16            Jiangsu    4 d               F to M                    3     p.Gly203Ser/p.Arg227Gln
  17            Henna      14 yr             F to M                    2.5   c.698+2T\>C/c.698+2T\>C
  18            Zhejiang   12 yr             F to M                    2.5   p.Arg246Gln/p.Arg246Gln
  19            Anhui      18 yr             F to M                    2.5   p.Arg246Gln/p.Asn193Ser
  20            Jiangxi    17 yr             F to M                    3     p.Gly203Ser/p.Arg246Gln
  21            ---        18 yr             M                         9     p.Gly203Ser/c.182-2A\>G
  22            ---        23 yr             F to M                    3     p.Gly203Ser/c.182-2A\>G
  23            Jiangxi    16 yr             F to M                    3     p.Ala228Val/p.Ala228Val
  24            Henan      23 yr             F to M                    2.5   p.Ala228Val/p.Ala228Val
  25            Shandong   16 yr             F to M                    2     p.Gln6∗/p.Gly203Ser

F: female; M: male; EMS: external masculinization score. \-\-- indicates no mutation in another chromosome.

###### 

Comparison of hormone levels between patients with and without p.GLY203SER mutation.

          GLY203SER (*n* = 8)   Other variants (*n* = 17)   *P* value
  ------- --------------------- --------------------------- -----------
  LH      6.58 ± 4.24           8.82 ± 6.00                 0.36
  FSH     5.94 ± 3.03           14.36 ± 11.09               0.05
  T       19.27 ± 12.97         20.74 ± 11.25               0.77
  DHT     0.56 ± 0.37           0.49 ± 0.28                 0.61
  T/DHT   40.28 ± 26.10         52.05 ± 34.17               0.41
  EMS     4.25 ± 2.49           3.06 ± 1.80                 0.19

EMS: external masculinization score.

###### 

Comparison of hormone levels between patients with and without p.GLN6∗ mutation.

          GLN6∗ (*n* = 7)   Other variants (*n* = 18)   *P* value
  ------- ----------------- --------------------------- -----------
  LH      8.47 ± 6.53       7.91 ± 5.21                 0.83
  FSH     16.35 ± 12.47     9.85 ± 8.65                 0.15
  T       20.25 ± 12.29     20.28 ± 11.65               1.00
  DHT     0.35 ± 0.19       0.57 ± 0.33                 0.15
  T/DHT   64.03 ± 41.28     42.28 ± 26.49               0.15
  EMS     2.14 ± 0.38       3.94 ± 2.25                 0.05

EMS: external masculinization score.

###### 

Frequencies of the haplotypes with p.Gln6∗ mutation in 12 cases and 1468 controls.

  SNP                Mutation   Location   Chr. position   Nucleotide change   Haplotype 1   Haplotype 2   Haplotype 3   
  ------------------ ---------- ---------- --------------- ------------------- ------------- ------------- ------------- ---
  Rs12470143                    Intron 1   31763558        C\>T                C             T             C             
  Rs12470196                    Intron 1   31763752        C\>T                C             T             C             
  Rs57971483                    Intron 1   31765510        C\>T                T             C             T             
  Rs4952220                     Intron 1   31765556        A\>C                C             A             C             
  Rs2300697                     Intron 1   31786637        C\>T                C             T             T             
  Rs2300698                     Intron 1   31786793        A\>G                A             G             G             
  Rs2300699                     Intron 1   31786967        G\>T                G             T             T             
  Rs2300700                     Intron 1   31786992        A\>G                G             A             G             
  Rs2300701                     Intron 1   31787008        A\>G                A             G             G             
  Rs522638                      Intron 1   31805675        A\>G                A             G             G             
  Rs523349                      Exon 1     31805706        C\>G                G             C             C             
  Rs632148                      5′-UTR     31806031        C\>G                C             G             G             
  Control (allele)                                                             1494          250           936           
                     p.Gln6∗    Exon 1     31805954        C\>T                T             C             C             T
  Case (allele)                                                                5             5             1             1
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